Kevin Claybrook, MD
Urology · Little Rock, ARNPI 1578538229
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $111,000 of the $131,696 with a category attached, or 84.3%. Cryo Specialty Medical, LLC accounts for 94.5% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $38,500 and has fallen 97.3% since, to $1,058 in 2025. Among urology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $396.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cryo Specialty Medical, LLC$125K
- Coloplast$2K
- Johnson & Johnson$716
- Sumitomo Pharma America, Inc.$522
- Dendreon Pharmaceuticals LLC$400
- Pfizer$395
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$13,50010%
- Food & beverage$7,1965%
- Ownership interest$111,00084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cryo Specialty Medical, LLC | 5 | $124,500 |
| Coloplast | 93 | $1,927 |
| Johnson & Johnson | 22 | $716 |
| Sumitomo Pharma America, Inc. | 23 | $522 |
| Dendreon Pharmaceuticals LLC | 15 | $400 |
| Pfizer | 22 | $395 |
| Astellas Pharma US Inc | 20 | $362 |
| AbbVie(2 entities) | 20 | $356 |
| Novartis | 19 | $355 |
| Myovant Sciences Inc. | 12 | $319 |
| Boston Scientific | 6 | $295 |
| Myriad Genetic Laboratories, Inc. | 9 | $280 |
| Verity Pharmaceuticals Inc. | 8 | $186 |
| Bayer | 7 | $124 |
| Blue Earth Diagnostics | 7 | $116 |
| Teleflex LLC | 6 | $107 |
| Urogen Pharma, Inc. | 5 | $92 |
| Axonics, Inc. | 4 | $90 |
| Amgen | 4 | $82 |
| Neotract Inc. | 4 | $73 |
| Ferring Pharmaceuticals Inc. | 3 | $72 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $58 |
| Olympus America Inc. | 2 | $38 |
| Procept Biorobotics Corporation | 2 | $37 |
| Agiliti Health, Inc. | 1 | $28 |
| Urovant Sciences Inc | 2 | $26 |
| Medtronic | 1 | $22 |
| Photocure Inc | 1 | $21 |
| Clovis Oncology, Inc. | 1 | $19 |
| Baudax Bio Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Rochester Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$362
- ORGOVYX$250
- TITAN$185
- PROVENGE$120
- GENERAL ERECTILE DYSFUNCTION$114
- BRAC CDx$111
- GENERAL KIDNEY STONE DISEASE$100
How this compares
$131,696 in reported general payments places this provider in the 90th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 109 | $67,152 |
| GemtesaVibegron | 74 | $44,878 |
| Tamsulosin Hcl | 1,894 | $25,786 |
| Oxybutynin Chloride ErOxybutynin Chloride | 295 | $5,952 |
| Methenamine Hippurate | 88 | $5,701 |
| Potassium Citrate ErPotassium Citrate | 41 | $4,165 |
| Testosterone | 12 | $4,138 |
| Dutasteride | 134 | $4,050 |
| Finasteride | 365 | $3,661 |
| Solifenacin Succinate | 63 | $2,984 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 104 | $1,476 |
| Oxybutynin Chloride | 128 | $1,101 |
| Estradiol | 14 | $1,000 |
| Silodosin | 17 | $864 |
| Doxazosin Mesylate | 36 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $362 | $67,152109 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $522 | $44,87874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 urology providers in Arkansas.
Other urology in Little Rock
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Gail JonesLittle Rock$128K
- John MooreLittle Rock$19K
- Michael ChildsLittle Rock$8K
- Bruno Lopes Cancado MachadoLittle Rock$7K
- Marcelo BigarellaLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.